Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXM01 in recurrent glioblastoma
NCT02718443Phase 1Completed
- Sponsor
- Vaximm
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- DNA Vaccines, Live Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vxm01 in glioblastoma (GBM), sponsored by Vaximm. Primary endpoint: Safety and tolerability taking into account treatment-limiting toxicities (TLTs) at 12 months. Started May 2016; status: completed.
02
Drugs
vxm01
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02718443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718443.